. Author manuscript; available in PMC: 2018 Oct 22.

Published in final edited form as: Breast Cancer Res Treat. 2015 Oct 28;154(2):309–318. doi: 10.1007/s10549-015-3604-z

Table 3.

Pre and post intervention levels of estrogen and progesterone (urinary conjugate, ng/mL) and hormonally sensitive breast tissue (MR imaging) among premenopausal women at elevated risk for breast cancer (N = 135 for hormonal data, N = 68 for imaging data)

	N	Pre level [95 % CI]			Post level [95 % CI]

		Control	Low dose	High dose	Control	Low dose	High dose

Estrogen (ng/mL)
Follicular	135	790 [687, 908]	785 [674, 915]	802 [694, 927]	882 [767, 1014]	769 [659, 898]	804 [693, 932]
Luteal	135	499 [418, 599]	487 [400, 592]	541 [449, 651]	519 [434, 621]	511 [419, 624]	579 [479, 702]
Progesterone (ng/mL)
Follicular	135	18.8 [15.5, 22.8]	19.5 [15.8, 24.0]	19.2 [15.7, 23.4]	20.0 [16.5 24.2]	20.2 [16.3, 25.0]	18.1 [14.7, 22.2]
Luteal	135	54.1 [44.7, 65.6]	62.2 [50.4, 76.7]	61.3 [50.2, 74.8]	51.2 [42.2, 62.1]	57.7 [46.5, 71.5]	66.6 [54.2, 81.9]
Imaging outcome (cm²)
Background parenchymal enhancement (cm²)	68^a	263 [213, 326]	268 [214, 337]	265 [215, 327]	317 [256, 392]	289 [229, 364]	234 [188, 292]

Measured in a subset of participants, image acquisition during follicular phase at months 1 and 7